Home / Drugs / spesolimab-sbzo

spesolimab-sbzo

FDA Drug Profile — SPEVIGO

Drug Details

Generic Name
spesolimab-sbzo
Brand Names
SPEVIGO
Application Number
BLA761244
Sponsor
Boehringer Ingelheim Pharmaceuticals, Inc.
NDC Codes
3
Dosage Forms
INJECTION
Routes
INTRAVENOUS
Active Ingredients
SPESOLIMAB

Indications and Usage

1 INDICATIONS AND USAGE SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. SPEVIGO is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. ( 1 )